Endocrine disorders and prostate cancer drugs

Question 1

Pegvisomant

Answer 1

GH analogue and competitive inhibitor
-prevents IGF secretion
——–
-Acromegaly
——-
-Elevated liver enzymes

Question 2

Growth hormone

Answer 2

-stimulate growth
-activate IGF production
——–
-dwarfism
-turners syndrome
-illicit drug for body building
——
-Carpal tunnel syndrome
-cardiomegaly

Question 3

Octreotide

Answer 3

somatostatin analogue
-signals by somatostatin receptor 2/5)
-inhibits GH secretino
——
-Acromegaly
——
-Sinus bradycardia
-GI upset
-headache/fatigue
-messes up a bunch of other hormones

Question 4

Lanreotide

Answer 4

somatostatin analogue
-inhibits GH secretion
——
-Acromegaly
——
-Sinus bradycardia
-GI upset
-headache/fatigue
-messes up a bunch of other hormones

Question 5

Pasiretotide

Answer 5

somatostatin analogue
-inhibits GH secretion
——
-Acromegaly
——
-Sinus bradycardia
-GI upset
-headache/fatigue
-messes up a bunch of other hormones

Question 6

Female HRT

Answer 6

/
counteracts low sex hormones
——-
-menopausal Sx, mood changes, hot flashes
-prevent osteoporosis
-does not effect heart disease
———-
-endometrial cancer (progestogen)
-breast cancer

Question 7

Testosterone

Answer 7

/
Acts on androgen receptor
———–
-hypogonadism from pituitary or testicular issues
-female hypo sexuality following ovariectomy
———
-infertility
-salt and water retention
-acne

Question 8

Gonadorelin

Answer 8

GnRH analogue
-chronic release inhibits FSH and LH, usually pulsatile
———-
-hyperandrogegism
-prostate cancer
———-
-starts with surge of testosterone release
-low libido

Question 9

Degarelix

Answer 9

reservable GnRH receptor inhibitor
-rapid androgen decrease
——–
-postate cancer
———
-Hot flash/flush

Question 10

Bicalutamide

Answer 10

Non-steroidal anti androgen
-competes for androgen binding sites in tissues
——-
-postate cancer alone
-or limit effect of testosterone surge from other treatments

Question 11

Abiraterone

Answer 11

androgen biosynthesis inhibitor
-inhibits CYP17 which is needed for androgen synthesis in tumours
——-
-prostate cancer
——-
-peripheral edmea

Question 12

Finasteride

Answer 12

/
5 alpha reductase inhibitor, prevents testosterone to DHT conversion
——–
-benign prostatic hyperplasia
-alopecia
——–
-Reduced libido

Question 13

Minoxidil

Answer 13

/
Vasodilator to increase blood flow to hair follicles
——-
-alopecia
——–
-starts with low then growth

Question 14

Eflornithine

Answer 14

/
Irreversibly inhibits ornithine decarboxylase preventing hair follicle growth
——–
-hirsutism
——–
-acne

Question 15

Bromocriptine

Answer 15

/
D2 agonist
———
-hyperprolactinemia
-galactorrhea
——
-postural hypotension

Question 16

Carbergoline

Answer 16

/
D2 agonist
———
-hyperprolactinemia
-galactorrhea
——
-postural hypotension

Question 17

Quinagolide

Answer 17

/
D2 agonist
———
-hyperprolactinemia
-galactorrhea
——
-postural hypotension

Question 18

Prednisolone

Answer 18

/
Glucocorticoid
——–
-addisons disease

Question 19

Fludrocortisone

Answer 19

-stimulates a mineralocorticoid effect (like aldosterone)

Question 20

Pasireotide

Answer 20

/
Somatostatin reactor type 5 agonist to decrease ACTH release
——–
-cushings syndrome

Question 21

Cabergoline

Answer 21

D2 agonist
-inhibit action
——-
-cushings syndrome

Question 22

Ketoconazole

Answer 22

/
P450 inhibitor which prevent steroid synthesis
——-
-cushings

Question 23

Metyrapone

Answer 23

/
11 beta hydroxylate inhibitor to prevent steroid synthesis
——-
-cushings

Question 24

Enzalutamide

Answer 24

Non-steroidal anti androgen
-competes for androgen binding sites in tissues
——-
-postate cancer alone
-or limit effect of testosterone surge from other treatments

Question 25

Flutamide

Answer 25

Non-steroidal anti androgen
-competes for androgen binding sites in tissues
——-
-postate cancer alone
-or limit effect of testosterone surge from other treatments

Question 26

Nilutamide

Answer 26

Non-steroidal anti androgen
-competes for androgen binding sites in tissues
——-
-postate cancer alone
-or limit effect of testosterone surge from other treatments

Question 27

Cyproterone

Answer 27

Non-steroidal anti androgen
-competes for androgen binding sites in tissues
——-
-postate cancer alone
-or limit effect of testosterone surge from other treatments